Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.

Vinge advises Haki Safety in connection with rights issue

Vinge advises Haki Safety AB (publ) in connection with a rights issue of approximately SEK 50 million.

Vinge advisor in connection with Klarna's IPO on the New York Stock Exchange

Vinge, together with Latham & Watkins, acted as advisor to bookrunners and managers in connection with the listing of Klarna, the global digital bank and provider of flexible payment solutions, on the New York Stock Exchange.

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.

Vinge advises Intrum on its EUR 4.48 billion recapitalisation transaction

Intrum AB and its subsidiaries have completed a comprehensive and strategic recapitalisation transaction aimed at strengthening the company's balance sheet and securing its long-term financial stability. The transaction involves a restructuring of Intrum's existing debt portfolio of approximately EUR 4.48 billion and includes, among other things, an extension of loan maturities, write-downs of existing debt instruments, the injection of new capital from certain of the company's noteholders, and a share issue to existing noteholders. The recapitalisation transaction was implemented through a pre-packaged Chapter 11 process in the United States and a Swedish company reorganisation.

Vinge advises Isofol Medical AB (publ) in connection with its rights issue of units

Through the rights issue of units, consisting of shares and warrants, and the exercised over-allotment issue, Isofol will receive approximately SEK 84 million and may receive an additional maximum of approximately SEK 110 million upon exercise of all warrants at the highest subscription price.

Vinge advises Oncorena in connection with share issue

Vinge advises Oncorena Holding AB in connection with a share issue of approximately SEK 133 million.

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.

Vinge advises The Qt Company Ltd on its public offer for I.A.R. Systems Group AB (publ)

The Qt Company Ltd (“The Qt Company”), a wholly owned subsidiary of Qt Group Plc, has announced a public tender offer to the shareholders of I.A.R. Systems Group AB (publ) (“IAR”) to tender all class B shares in IAR to The Qt Company at a price of SEK 180 in cash per share

Vinge has advised Terranor Group AB in connection with its listing on Nasdaq First North Growth Market

Vinge has advised Terranor Group AB (publ) (“Terranor”) connection with its listing on Nasdaq First North Growth Market. The first day of trading in Terranor's shares is today 30 June 2025.

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.

Vinge has advised Sveafastigheter in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Sveafastigheter AB (publ) in connection with its list change from Nasdaq First North Premier Growth Market to Nasdaq Stockholm. The prospectus was published on 13 June 2025 and the trading on Nasdaq Stockholm commenced on 18 June 2025.

Vinge advises Armada Investment AG on its investment in Studsvik

Armada Investment AG, the Zurich-based entrepreneurial investment firm led by Daniel S. Aegerter, has increased its shareholding in Studsvik to 29.9% of outstanding shares. The investment builds on Armada's initial 9.9% stake acquired in February 2025. The shares of Studsvik are admitted to trading on Nasdaq Stockholm. Armada has invested across the nuclear supply chain for over a decade, with portfolio companies including Oklo, Commonwealth Fusion Systems, Proxima Fusion, Last Energy, and Blykalla.

Vinge advises EHF Invest on its public offer for Real Fastigheter

EHF Invest AB has made a public offer for all shares in Real Fastigheter AB (publ).